#21. Edwards Lifesciences Corp (EW) — 27% UPSIDE

Edwards Lifesciences is engaged in patient-focused medical for structural heart disease, as well as critical care and surgical monitoring. Co. is a manufacturer of heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. Co. is also engaged in hemodynamic and noninvasive brain and tissue oxygenation monitoring systems used to measure a patient's cardiovascular function in the hospital setting. Co.'s products and technologies are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. The median 12 month forward target price among analysts covering EW is $85.0/share.